|
市場調查報告書
歐洲，美國，日本OTC藥品的機會 : 主要動向，主要企業，將來的處方藥改為OTC的變化動向
OTC Opportunities in Europe, the US and Japan: Key trends, leading players and future Rx-OTC switching
|
歐洲，美國，日本OTC藥品的機會 : 主要動向，主要企業，將來的處方藥改為OTC的變化動向 是由出版商Business Insights在2010年01月所出版的。
這份英文市場調查報告書包含125 pages 價格從美金3835起跳。
本報告書對於歐洲，美國，日本的處方藥改為OTC的變化動向作了分析，亦有法規的變化與到2013年的成長預測，概述如下。
總綱
第1章 緒論
第2章 歐洲的OTC動向與機會
- 綱要
- 緒論
- 法規背景
- OTC市場動向
- 近年發展
- 新的機會
第3章 美國的OTC動向與機會
- 綱要
- 緒論
- 法規背景
- OTC市場動向
- 近年發展
- 新的機會
第4章 日本的OTC動向與機會
- 綱要
- 緒論
- 法規背景
- OTC市場動向
- 近年發展
- 新的機會
第5章 Orlistat與Statin的轉換經驗分享
第6章 結論與預測
第7章 附錄
圖表
Abstract
The developed OTC markets such as the US and UK are heavily reliant on
Rx-to-OTC switching of "new generation" products as a means of generating
growth. Switching also plays an important role for less-developed markets
(e.g. France, Spain, Italy, Japan), though in this case they are playing
"catch-up" with the more developed markets. The "Power of Switch" was brought
into sharp focus in 2009 with the first ever use of the Centralized Procedure
for switching products throughout the European Union. This comprehensive
report provides background on market dynamics (including overall market size
and therapeutic category size) for each of the core countries under analysis.
This report also examines products and categories that are likely to be
switched in the future, regulatory changes that are likely to impact the OTC
market, and provides growth forecasts to 2013. Included in the report are case
studies for two of the most significant switches of recent years - i.e. Alli
(orlistat) and Zocor (simvastatin).
Table of Contents
Executive summary
- Introduction
- OTC opportunities in Europe
- OTC opportunities in the US
- OTC opportunities in Japan
- Case studies of major Rx-to-OTC switches
- Conclusions and forecasts
Chapter 1 Introduction
- Summary
- OTC market in context
- General growth drivers
- The power of switch
- Attitudes to switch
- Switch drivers
- Definitions
Chapter 2 OTC trends and opportunities in Europe
- Summary
- Introduction
- Regulatory background
- Rx-to-OTC switch mechanism
- OTC market dynamics
- France
- Germany
- Italy
- Spain
- UK
- Key recent developments
- Centralized Procedure for Rx-to-OTC switching makes debut in 2009
- OTC pantoprazole
- OTC Viagra ruled to be too risky
- France
- Low switch
- De-reimbursement
- Line extensions
- Self selection of OTCs introduced in 2008
- Germany
- Italy
- Spain
- UK
- Pioneering switch
- Tamsulosin to become world' s first BPH treatment available OTC
- P-to-GSL switching
- Leading new products
- New opportunities
- Momentum gathers to increase OTC accessibility in France and Italy
- Self-selection in France
- Government proposes "starter OTCs" for mass market in Italy
- Rx-to-OTC switch opportunities
- Collaborative care
- UK has several switches in the pipeline
- "Unofficial" OTCs
- Comparison with other regions
- Stakeholder attitudes to switches
Chapter 3 OTC trends and opportunities in the US
- Summary
- Introduction
- Regulatory background
- OTC market dynamics
- Key recent developments
- Recent switches make major impact
- Cetirizine
- Orlistat
- Omeprazole + sodium bicarbonate
- Switch of lovastatin stalls
- New opportunities
- Foreign switches provide possible switch candidates for the US
- FDA proposes new BTC drug category
- Consumers are ready to embrace BTC drugs
- Price implications of BTC products
Chapter 4 OTC trends and opportunities in Japan
- Summary
- Introduction
- Regulatory background
- Rx-to-OTC switch procedure
- OTC market dynamics
- Key recent developments
- Rx-to-OTC switching
- Opening up of mass market
- Sales implications of new OTC classifications
- New opportunities
Chapter 5 Case studies of switches of orlistat and statins
- Summary
- Introduction
- Orlistat
- Australia establishes switch model for orlistat
- US switch model
- European switch model
- Availability of orlistat OTC continues to face resistance
- Sales performance
- Future prospects
- Statins
- Simvastatin
- Sales of Zocor Heart-Pro fail to meet expectations
- Other statins
- Long track record of failed attempts to switch statins in the US
- Future prospects for OTC statins
Chapter 6 Conclusions and forecasts
- Summary
- Introduction
- Main switch opportunities
- Collaborative care model facilitates new switches
- Regulatory challenges
- Forecasts
- France
- Germany
- Italy
- Spain
- UK
- US
- Japan
Chapter 7 Appendix Error! Bookmark not defined.
- References
- Abbreviations
- Index of companies
List of Figures
- Figure 2.1: Europe: OTC sales as proportion of total non Rx-bound* sales
($bn) in the Big Five markets, 2008
- Figure 2.2: France: OTC sales (RSP $m) by major therapeutic market, 2008
- Figure 2.3: Germany: OTC sales (RSP $m) by major therapeutic market, 2008
- Figure 2.4: Italy: OTC sales (RSP $m) by major therapeutic market, 2008
- Figure 2.5: Spain: OTC sales (RSP $m) by major therapeutic market, 2008
- Figure 2.6: UK: OTC sales (RSP $m) by major therapeutic market, 2008
- Figure 2.7: UK packaging for Flomax relief
- Figure 2.8: Key goals of AESGP' s Smart Regulation 2015
- Figure 2.9: Europe: Possible new areas for self-medication in
collaborative care setting
- Figure 3.10: US OTC sales (RSP $m) by major therapeutic market, 2008
- Figure 3.11: US packaging for Zegerid OTC
- Figure 4.12: Japan: OTC sales (RSP $m) by major therapeutic market, 2008
- Figure 4.13: Packaging Lipovitan D in Japan
- Figure 4.14: JSMI goals to 2014
- Figure 5.15: UK packaging for Alli
- Figure 6.16: Forecast OTC growth in key countries ($m), 2008-13
List of Tables
- Table 2.1: Europe: OTC classifications in the Big Five markets
- Table 2.2: Total pharmaceutical sales (RSP $m) in the Big Five EU markets,
2007-08
- Table 2.3: OTC sales (RSP $m) in the Big Five EU markets, 2007-08
- Table 2.4: UK: Recent Rx-to-OTC switches
- Table 2.5: UK: Products under review for switch from Rx-to-OTC*
- Table 3.6: US OTC sales ($m, RSP) 2006-08
- Table 3.7: US: OTC sales (RSP $m) by therapeutic category 2007-08
- Table 3.8: US: Rx-to-OTC switches, 2002-09
- Table 4.9: Japan: MHLW switch candidates, August 2008
- Table 4.10: Japan: JSMI switch candidates, 2007-08
- Table 7.11: Legal status of selected ingredients in key markets
- Table 7.12: Legal status of selected ingredients in key markets (ctd 1)
- Table 7.13: Legal status of selected ingredients in key markets (ctd 2)
|
